DE-CSC
16.6.2020 14:02:12 CEST | Business Wire | Press release
CSC , a world leader in business, legal, tax, and domain security, today released its 2020 Domain Security Report: Forbes Global 2000 Companies from their Digital Brand Services (DBS) division. The report highlights significant shortfalls in enterprise domain security practices, putting organizations’ internet-facing digital assets at risk to threats, including domain name and domain name system (DNS) hijacking, phishing, and other fraudulent activity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005062/en/
According to the report, 83% of Global 2000 organizations have not adopted basic domain security measures such as registry lock, which puts them at risk for domain name hijacking. The report indicates a wide industry disparity in domain security maturity with information technology and media and entertainment industries more likely to embrace available security controls, while industries such as materials and real estate trail behind.
“These security shortfalls are the direct result of not executing proper domain security techniques. Domain security cannot be an afterthought, and there needs to be a conscious effort to make this an intentional and critical part of every company’s overall cyber security posture, especially as criminals evolve their attack methods,” says Mark Calandra, executive vice president for CSC DBS. “As companies move to more online business models, it’s essential to use defense-in-depth practices to proactively manage, secure, and defend the foundational internet-facing components of your digital brand presence.”
Additional highlights from the report include:
- Four out of five Global 2000 companies are severely at risk and exposed to domain name and DNS hijacking due to a lack of registry locks. Unlocked domains are vulnerable to social engineering tactics, which can lead to unauthorized DNS changes and domain name hijacking.
- 53% of the Forbes Global 2000 use retail-grade domain registrars, putting them at greater risk for phishing, social engineering, and attacks while complicating compliance demands. The management of the overall domain name portfolio by a reputable corporate registrar versus a retail registrar will make the adoption of domain security standards much easier to implement and monitor.
- Only 20% of Global 2000 companies use enterprise-grade DNS hosting. Lack of DNS hosting redundancy and using non-enterprise-level DNS providers poses potential security threats like resiliency to distributed denial of service (DDoS) attacks, as well as down time, and revenue loss.
- 97% of the Global 2000 don’t use DNS security extensions (DNSSEC), which means the majority of companies are prone to cache poisoning attacks. Lack of deployment of DNSSEC leads to vulnerabilities in the DNS, which could include an attacker hijacking any step of the DNS lookup process.
- Domain-based message authentication, reporting, and conformance (DMARC) use is only at 39% for the Global 2000 companies. DMARC is an email validation system designed to protect a company’s email domain from being used for email spoofing, phishing scams, and other cyber crime.
A core division of CSC, DBS is the trusted provider of choice for the Forbes Global 2000 and is the only enterprise-class registrar with a comprehensive set of solutions focused on defending businesses from targeted threat vectors to their domain names, DNS, and digital certificates. Moreover, the organization detects and mitigates online brand abuse, infringements, and fraud with the latest machine analysis and scoring technology to perform global enforcement, including takedowns and advanced techniques in internet blocking.
If you’re a member of SANS, to learn more, join CSC and SANS for a webinar Friday, June 19. Register here .
External links:
- Download the report here
- Domain Security Report blog post
- Infographic for Domain Security Report
About CSC
CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system (DNS), digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005062/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
